(ANAB) AnaptysBio - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.758m USD | Total Return: 331.9% in 12m
Avg Turnover: 34.0M
Qual. Beats: -1
Rev. Trend: 98.7%
Qual. Beats: 0
Warnings
Negative Equity with losses - insolvent profile
Interest Coverage Ratio 0.6 is critical
Altman Z'' -4.53 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Leader, Confidence
AnaptysBio, Inc. is a San Diego-based clinical-stage biotechnology company specializing in immunology therapeutics for autoimmune and inflammatory diseases. The company utilizes a proprietary antibody platform to develop a pipeline targeting specific immune pathways, including programs such as Rosnilimab for rheumatoid arthritis and Imsidolimab for generalized pustular psoriasis. Its business model relies on advancing internal candidates through clinical milestones while leveraging strategic partnerships with GSK and Vanda to generate potential milestone and royalty revenue.
The biotechnology sector is characterized by high research and development costs and a lengthy regulatory approval process, often requiring companies to maintain significant capital reserves. Clinical-stage firms typically focus on de-risking assets through Phase 2 and Phase 3 trials to demonstrate efficacy and safety before seeking FDA marketing authorization. Investors looking for deeper fundamental analysis of the companys financial health may find ValueRay a useful tool for further research. AnaptysBio continues to focus on its CD122 and BDCA2 modulator programs to address unmet needs in celiac disease and interferon-mediated disorders.
- Rosnilimab Phase 2b clinical trial results drive volatility in rheumatoid arthritis market
- FDA approval and commercialization of Imsidolimab for generalized pustular psoriasis treatment
- Milestone payments and royalty revenue from GSK collaboration for dostarlimab sales
- Research and development expenses for early-stage pipeline candidates impact cash runway
- Clinical data readouts for ANB033 in celiac disease determine long-term valuation
| Net Income: -26.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 30.06 > 1.0 |
| NWC/Revenue: 118.1% < 20% (prev 285.2%; Δ -167.1% < -1%) |
| CFO/TA 0.01 > 3% & CFO 4.48m > Net Income -26.8m |
| Net Debt (4.51m) to EBITDA (53.3m): 0.08 < 3 |
| Current Ratio: 7.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (28.7m) vs 12m ago -6.37% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 61.83% > 50% (prev 26.51%; Δ 35.32% > 0%) |
| Interest Coverage Ratio: 0.62 > 6 (EBITDA TTM 53.3m / Interest Expense TTM 82.7m) |
| A: 0.83 (Total Current Assets 316.1m - Total Current Liabilities 41.7m) / Total Assets 329.7m |
| B: -2.50 (Retained Earnings -825.4m / Total Assets 329.7m) |
| C: 0.14 (EBIT TTM 50.9m / Avg Total Assets 375.9m) |
| D: -2.60 (Book Value of Equity -825.6m / Total Liabilities 316.9m) |
| Altman-Z'' = -4.53 = D |
| DSRI: 0.69 (Receivables 25.7m/17.9m, Revenue 232.4m/111.9m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.01 (AQ_t 0.00 / AQ_t-1 0.10) |
| SGI: 2.08 (Revenue 232.4m / 111.9m) |
| TATA: -0.09 (NI -26.8m - CFO 4.48m) / TA 329.7m) |
| Beneish M = -3.19 (Cap -4..+1) = AA |
As of May 24, 2026, the stock is trading at USD 59.71 with a total of 401,437 shares traded.
Over the past week, the price has changed by -5.45%,
over one month by +11.50%,
over three months by +64.98% and
over the past year by +331.85%.
AnaptysBio has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy ANAB.
- StrongBuy: 7
- Buy: 3
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 84.4 | 41.3% |
P/B = 136.4526
Revenue TTM = 232.4m USD
EBIT TTM = 50.9m USD
EBITDA TTM = 53.3m USD
Long Term Debt = 275.2m USD (estimated: total debt 277.4m - short term 2.12m)
Short Term Debt = 2.12m USD (from shortTermDebt, last quarter)
Debt = 291.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 13.6m
Net Debt = 4.51m USD (calculated: Debt 291.0m - CCE 286.5m)
Enterprise Value = 1.76b USD (1.76b + Debt 291.0m - CCE 286.5m)
Interest Coverage Ratio = 0.62 (Ebit TTM 50.9m / Interest Expense TTM 82.7m)
EV/FCF = 105.6x (Enterprise Value 1.76b / FCF TTM 16.7m)
FCF Yield = 0.95% (FCF TTM 16.7m / Enterprise Value 1.76b)
FCF Margin = 7.18% (FCF TTM 16.7m / Revenue TTM 232.4m)
Net Margin = -11.53% (Net Income TTM -26.8m / Revenue TTM 232.4m)
Gross Margin = unknown ((Revenue TTM 232.4m - Cost of Revenue TTM 2.42m) / Revenue TTM)
Tobins Q-Ratio = 5.35 (Enterprise Value 1.76b / Total Assets 329.7m)
Interest Expense / Debt = 28.42% (Interest Expense 82.7m / Debt 291.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = 40.2m (EBIT 50.9m * (1 - 21.00%))
Current Ratio = 6.42 (Total Current Assets 316.1m / Total Current Liabilities 49.2m)
Debt / Equity = 22.83 (Debt 291.0m / totalStockholderEquity, last quarter 12.7m)
Debt / EBITDA = 0.08 (Net Debt 4.51m / EBITDA 53.3m)
Debt / FCF = 0.27 (Net Debt 4.51m / FCF TTM 16.7m)
Total Stockholder Equity = -6.05m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.13% (Net Income -26.8m / Total Assets 329.7m)
RoE = -3.27% (Net Income TTM -26.8m / Total Stockholder Equity 819.4m)
RoCE = 4.65% (EBIT 50.9m / Capital Employed (Equity 819.4m + L.T.Debt 275.2m))
RoIC = 1.10k% (out of range, set to none) (NOPAT 40.2m / Invested Capital 3.65m)
WACC = 10.41% (E(1.76b)/V(2.05b) * Re(8.42%) + D(291.0m)/V(2.05b) * Rd(28.42%) * (1-Tc(0.21)))
Discount Rate = 8.42% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 51.11 | Cagr: 3.44%
[DCF] Terminal Value 68.56% ; FCFF base≈16.7m ; Y1≈16.8m ; Y5≈17.8m
[DCF] Fair Price = 6.87 (EV 204.4m - Net Debt 4.51m = Equity 199.9m / Shares 29.1m; r=10.41% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.03 | # QB: -1
Revenue Correlation: 98.68 | Revenue CAGR: 229.9% | SUE: 0.32 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.43 | Chg30d=+145.48% | Revisions=+43% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.48 | Chg30d=+151.18% | Revisions=+43% | Analysts=5
EPS current Year (2026-12-31): EPS=0.60 | Chg30d=+114.81% | Revisions=+43% | GrowthEPS=+231.3% | GrowthRev=-52.3%
EPS next Year (2027-12-31): EPS=5.92 | Chg30d=+267.44% | Revisions=+43% | GrowthEPS=+880.9% | GrowthRev=+37.8%
[Analyst] Revisions Ratio: +43%